Diabetes Mellitus and Heart Failure
Diabetes Mellitus and Heart Failure
复制标题
DOI：
10.1016/j.amjmed.2017.04.010
复制
发表时间：
2017-06-01
影响因子：
5.9
通讯作者：
Marx, Nikolaus
中科院分区：
文献类型：
--
作者：
Lehrke, Michael;Marx, Nikolaus
过去20年的流行病学和临床数据表明，糖尿病心力衰竭的患病率非常高，糖尿病心力衰竭患者的预后比非糖尿病心力衰竭患者更差。实验数据表明，各种机制导致糖尿病患者的收缩和舒张功能受损，并且越来越认识到这些患者发生心力衰竭与冠状动脉疾病或其相关危险因素的存在无关。此外，目前的临床数据表明，钠葡萄糖协同转运蛋白2抑制剂恩格列净治疗可减少心血管高风险的2型糖尿病患者因心力衰竭住院治疗。这篇综述文章总结了糖尿病合并心力衰竭患者的患病率、预后、病理生理学和治疗策略的最新数据。(C)2017作者由爱思唯尔公司出版
Epidemiologic and clinical data from the last 2 decades have shown that the prevalence of heart failure in diabetes is very high, and the prognosis for patients with heart failure is worse in those with diabetes than in those without diabetes. Experimental data suggest that various mechanisms contribute to the impairment in systolic and diastolic function in patients with diabetes, and there is an increased recognition that these patients develop heart failure independent of the presence of coronary artery disease or its associated risk factors. In addition, current clinical data demonstrated that treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin reduced hospitalization for heart failure in patients with type 2 diabetes mellitus and high cardiovascular risk. This review article summarizes recent data on the prevalence, prognosis, pathophysiology, and therapeutic strategies to treat patients with diabetes and heart failure. (C) 2017 The Authors. Published by Elsevier Inc.